SCHOTT recently introduced syriQ BioPure®, pre-fillable glass syringes for the biologics market, which are designed to keep sensitive drugs stable over shelf life and shorten time to market while making administration more convenient for patients. “Sensitive and complex drugs are often highly viscous, which makes them more difficult to administer,” said Nicolas Eon, Ph.D., global product manager. “Furthermore, they are prone to interaction with the container due to their complex molecule structure.”

syriQ BioPure syringes are reportedly manufactured under improved processes to lower tungsten and adhesive residuals and to ensure a uniform silicone layer—all validated and documented according to the latest U.S. Food and Drug Administration guidelines. According to SCHOTT, the syringes are made of highly inert FIOLAX® borosilicate glass, which is suitable for packaging complex drug products.

The new glass syringes work with leading safety and auto-injector devices, meeting market demand for products that can be administered at home for patient comfort. Integration into these devices is reached due to the syringe’s high dimensional accuracy. Glass tubing is inspected with SCHOTT’s big data perfeXion™ process, while additional dimensions beyond ISO requirements and new geometrical tolerances are achieved with the company’s forming technology and online inspection systems.

syriQ BioPure syringes are available with a range of coated plunger stoppers tailored for sensitive applications. More than 48 combinations have been validated. Options include various closure systems, such as Aptar 4800, Aptar 4900, West 7025 and West 7028.

For more information, visit www.schott.com.